at page 9, line 14, after "(TBI)", the words -- obsessive-compulsive disorder (OCD) -- are inserted;

at page 9, line 19, "accepable" is deleted and -- acceptable -- is substituted therefor;

at page 9, line 30, delete "amylotropic" and substitute therefor -- amyotrophic --;

at page 9, line 32, delete "supramuscular" and substitute therefor -- supranuclear --;

at page 9, line 34, delete "barbituates" and substitute therefor -- barbiturates --;

at page 9, line 35, after "(TBI)", the words -- obsessive-compulsive disorder (OCD) -- are inserted;

at page 23, line 13, "dichoroethane" is deleted and -- dichloroethane -- is substituted therefor;

at page 24, line 9, "heteratoms" is deleted and -- heteroatoms -- is substituted therefor;

at page 24, line 10, "heteroryl" is deleted and -- heteroaryl -- is substituted therefor;

at page 25, line 8, "illlustrated" is deleted and -- illustrated -- is substituted therefor;

at page 25, line 16, "exemplied" is deleted and -- exemplified -- is substituted therefor;

at page 27, line 7, "stoicheometric" is deleted and -- stoichiometric -- is substituted therefor;

at page 27, line 8, "pyridinum" is deleted and -- pyridinium -- is substituted therefor;

at page 31, line 17, "trifluromethansulfonic" is deleted and -- trifluoromethanesulfonic -- is substituted therefor;

at page 31, line 24, "acylations" is deleted and -- acylation -- is substituted therefor;

at page 31, line 36, "substited" is deleted and -- substituted -- is substituted therefor;

IN THE CLAIMS

Cancel claims 3, 4, 5, 6, 7, 11, 12 and 13.

Replace claims 1, 2, 9, 10 and 14 with the amended versions immediately following:

1. (Once Amended) A compound of the formula



(I)

R^1 is hydrogen, $(C_1$ -$C_6)$alkyl, unconjugated $(C_3$-$C_6)$alkenyl, $XC(=O)R^{13}$, benzyl or $-CH_2CH_2$-O-$(C_1$-$C_4)$alkyl;

79

R^2 and R^3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents that are selected, independently, from (C_1 -C_6) alkyl optionally substituted with from one to seven fluorine atoms; (C_1-C_6)alkoxy optionally substituted with from one to seven fluorine atoms; nitro, cyano, halo, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, amino, (C_1 -C_6)alkylamino and ((C_1 -C_6)alkyl)$_2$amino, -CO_2R^4, -$CONR^5R^6$, -$SO_2NR^7R^8$, -$C(=O)R^{13}$ and -$XC(=O)R^{13}$;

wherein each R^4, R^5, R^6, R^7, R^8 and R^{13} is selected, independently, from hydrogen and (C_1 -C_6) alkyl, or R^5 and R^6, or R^7 and R^8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C_1-C_6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C_1-C_6)alkylene;

or a pharmaceutically acceptable salt thereof.

2. (Once Amended) A compound according to claim 1, wherein R^2 and R^3, together with the benzo ring of formula I, form a bicyclic ring system selected from the following:



wherein R^{10} and R^{17} are selected, independently, from (C_1-C_6) alkyl optionally substituted with from one to seven fluorine atoms; (C_1 -C_6) alkoxy optionally substituted with from one to seven fluorine atoms; (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, amino, (C_1 -C_6)alkylamino and ((C_1 -C_6) alkyl)$_2$amino, -CO_2R^4, -$CONR^5R^6$, -$SO_2NR^7R^8$, -$C(=O)R^{13}$ and -$XC(=O)R^{13}$ and wherein R^4, R^5, R^6, R^7, R^8 and R^{13} are as defined in claim 1.

12

9. (Once Amended) A pharmaceutical composition comprising an amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

14

10. (Once Amended) A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

14. (Once Amended) A compound of the formula



(I′)

wherein R^2 and R^3 are defined as in claim 1; and P′ is $COOR^{16}$ wherein R^{16} is allyl, 2,2,2-trichloroethyl or $(C_1\text{-}C_6)$alkyl; $-C(=O)NR^5R^6$ wherein R^5 and R^6 are selected, independently, from hydrogen and $(C_1\text{-}C_6)$ alkyl, or R^5 and R^6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-$(C_1\text{-}C_6)$alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; -C(=O)H, $-C(=O)(C_1\text{-}C_6)$alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms; benzyl, or t-butoxycarbonyl (t-Boc).

Add new claims 15 through 26.

-- 15. A compound according to claim 1 selected from the group consisting of: 5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;

7-methyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
6-methyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
7-propyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
7-butyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
7-phenyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
7-neopentyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,6,8-tetraene;
and pharmaceutically acceptable salts thereof. --

-- 16. A compound according to claim 1 selected from the group consisting of:
6-methyl-5,7-dioxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
5,7-dimethyl-6-oxo-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
5,7-dioxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
5-oxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
6-oxo-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
6-methyl-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,6,8-tetraene;
7-dimethylamino-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,6,8-tetraene;
6,7-dioxo-5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]hexadeca-2(11),3,9-triene;
5,8-dimethyl-6,7-dioxo-5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]hexadeca-2(11),3,9-triene;
5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,8-triene;
and pharmaceutically acceptable salts thereof. --

-- 17. A compound according to claim 1 which is:
6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,6,8-tetraene;
or a pharmaceutically acceptable salt thereof. --

-- 18. A compound according to claim 1 which is:
6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.$0^{2,10}$.$0^{4,8}$]pentadeca-2(10),3,5,8-tetraene;
or a pharmaceutically acceptable salt thereof. --